



The Royal New Zealand
College of General Practitioners
Te Whare Tohu Rata o Aotearoa

27 November 2025

Pharmac
PO Box 10254
The Terrace
WELLINGTON 6143

By email: consult@pharmac.govt.nz

Tēnā koe,

Pharmac proposal to fund another ADHD medicine to improve supply

The Royal New Zealand College of General Practitioners supports Pharmac's proposal to fund Rubifen LA (long-acting methylphenidate) from 1 July 2026. This is an important step to address ongoing global supply shortages that have disrupted access to ADHD medicines since 2023.

Funding Rubifen LA will:

- Increase overall supply and reduce the risk of shortages.
- Provide clinicians and patients with more treatment options, including a new 60 mg strength.
- Improve continuity of care and reduce stress for families affected by medicine unavailability.

We encourage Pharmac to proceed with this proposal to ensure equitable and reliable access to ADHD medicines across Aotearoa.

Nāku noa, nā

Dr Prabani Wood
BA, BMBCh, MPH, FRNZCGP
Medical Director | Mātanga Hauora

About the College

Level 4, 50 Customhouse Quay, Wellington 6011 | PO Box 10440, Wellington 6140, New Zealand
0800 965 999 | +64 4 496 5999 | rncgp@rncgp.org.nz | rncgp.org.nz